Keyphrases
Advanced Colorectal Cancer
50%
Adverse Event Rates
24%
Algal Oil
50%
Allogeneic
26%
Barcoding
50%
Biochemical Response
20%
Biogenic Synthesis
50%
Biological Production
50%
Carbohydrate Antigen 19-9 (CA19-9)
16%
CD68
16%
Cellular Phenotype
25%
Colon
50%
Colorectal Cancer
40%
Confidence Interval
77%
Cyclophosphamide
100%
Docetaxel
50%
Fluorescence-activated Cell Sorting
25%
High Dose
50%
High-throughput Phenotyping
50%
Immune-related Response Criteria
16%
In(III)
16%
Intravenous Vitamin C
50%
Listeria
50%
Measurable Disease
16%
Median Overall Survival
30%
Mesothelin
50%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
50%
Mismatch Repair
50%
Myeloid Cells
16%
Nivolumab
50%
Objective Response
43%
Overall Survival
53%
Oxylipins
25%
Pancreas
50%
Pancreatic Adenocarcinoma
16%
Pancreatic Cancer
50%
Pancreatic Tumor Cells
16%
PD-1 Inhibitor
20%
Pembrolizumab
50%
Phase II Study
50%
Phase II Trial
50%
Piglet Feeding
50%
Previously Treated
16%
Randomized Placebo-controlled Trial
50%
Resolvins
50%
Response Evaluation Criteria in Solid Tumors (RECIST)
36%
Reverse Transcription
50%
Safety Sequence
25%
T Cell Receptor
50%
Tumor Response
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
46%
Anti-Inflammatory Drug
14%
Arachidonic Acid
50%
Ascorbic Acid
50%
Carcinoembryonic Antigen
20%
Castration Resistant Prostate Cancer
50%
CD8 Antigen
12%
Cervonic Acid
12%
Chlordane
12%
Cis Fatty Acid
12%
Collagen-Induced Arthritis
50%
Colon Cancer
25%
Colorectal Cancer
100%
Cyclophosphamide
100%
Disease
22%
DNA Methyltransferase Inhibitor
25%
Docetaxel
50%
Docosahexaenoic Acid
58%
Docosapentaenoic Acid
100%
Enzyme-Linked Immunosorbent Assay
12%
Fatty Acid
50%
Granulocyte Macrophage Colony Stimulating Factor
35%
Guadecitabine
50%
Hemolytic Anemia
10%
Icosapentaenoic Acid
25%
Inflammation
50%
Joint Destruction
50%
Listeria
50%
Malignant Neoplasm
11%
Mesothelin
50%
Metastasis
12%
Monotherapy
10%
Mouse
50%
Neoplasm
12%
Nivolumab
50%
Overall Survival
77%
Oxylipin
25%
Pancreas Adenocarcinoma
12%
Pancreas Cancer
50%
Pancreas Tumor
12%
Pembrolizumab
50%
Pharmacodynamics
50%
Phase II Trials
50%
Piglet
50%
Placebo
50%
Progression Free Survival
40%
Rheumatoid Arthritis
18%
Solid Malignant Neoplasm
20%
Tumor Antigen
10%
Tumor Microenvironment
37%
Immunology and Microbiology
Adaptive Immune System
12%
Adoptive Immunity
10%
Alpha Chain
12%
Antigen Specificity
12%
Antiinflammatory Activity
10%
Arm
60%
Arthritis
50%
B Cell
12%
Beta Chain
12%
Calnexin
16%
Carcinoembryonic Antigen
20%
CD4
12%
CD8
12%
Cell Antigen
12%
Colon
50%
Cyclophosphamide
100%
DBA 1 Mouse
10%
ELISA
20%
Fluorescence Activated Cell Sorting
25%
Freund's Adjuvant
10%
Granulocyte Macrophage Colony-Stimulating Factor
10%
Immunotherapy
10%
Inflammatory Arthritis
30%
Information Retrieval
12%
interferon
10%
Listeria
50%
Low Drug Dose
10%
Mesothelin
50%
Mismatch Repair
50%
Monospecific Antibody
10%
Mouse
50%
Mouse Model
10%
Nivolumab
50%
Overall Survival
34%
Pancreas
50%
Pembrolizumab
50%
Peptide Vaccine
12%
Peripheral Blood Mononuclear Cell
12%
Programmed Death 1 Receptor
10%
Progression Free Survival
23%
Regulatory T Cell
10%
Reverse Transcription
50%
RNA Sequence
12%
Splenocyte
10%
T Cell
12%
T Cell Receptor
50%
Transplant Rejection
10%
Tumor Antigen
10%
Vaccine Efficacy
53%
Whole Cell
10%
